SOGC / SCC Clinical Practice Guideline -...

SOGC/SCCClinicalPracticeGuideline

ColposcopicManagementofAbnormalCervicalCancerScreeningandHistology

TheseClinicalPracticeGuidelineshavebeenpreparedandapprovedbytheExecutiveandCounciloftheSocietyofCanadianColposcopists(SCC).TheseguidelineshavebeenapprovedbytheSOGC/GOC/SCCPolicyandPractice

GuidelinesCommittee,theSocietyofGynecologicOncologyofCanada(GOC)andtheExecutiveandCounciloftheSocietyofObstetriciansandGynaecologistsofCanada.

PrincipalAuthorJamesBentley,MBChB,Halifax,NS

TheExecutiveCounciloftheSocietyOfCanadianColposcopistsJamesBentley,MBChB,Halifax,NSMoniqueBertrand,MD,London,ONLizabethBrydon,MD,Regina,SKHeleneGagne,MD,Ottawa,ONBrianHauck,MD,Calgary,AB

Marie-HeleneMayrand,MD,Montreal,QCSusanMcFaul,MD,Ottawa,ONPattiPower,MD,St.John’s,NL

AlexandraSchepanski,MD,Edmonton,AB

SpecialContributorsLucyGilbert,MD,Montreal,QCJillNation,MD,Calgary,AB

MichaelShier,MD,Toronto,ONLauretteGeldenhuys,MD,Halifax,NSLindaKapusta,MD,Mississauga,ONTerryColgan,MD,Toronto,ON

RobertaHowlett,PhD,StThomas,ONJoanMurphy,MD,Toronto,ONRachelKupets,MD,Toronto,ON

DISCLOSURESTATEMENT

Disclosurestatementshavebeenreceivedfromallmembersofthecommittee(s).

DISCLAIMER

2of34

Thisdocumentreflectsemergingclinicalandscientificadvancesonthedateissued,

andissubjecttochange.Theinformationshouldnotbeconstruedasdictatingan

exclusivecourseoftreatmentorproceduretobefollowed.Localinstitutionscan

dictateamendmentstotheseopinions.Theyshouldbewelldocumentedifmodified

atthelocallevel.Noneofthesecontentsmaybereproducedinanyformwithout

priorwrittenpermissionoftheSOGC.

ABSTRACT

Objective:Todefineaguidelineformanagingabnormalcytologyresultsafterscreeningforcervicalcancerandtoclarifytheappropriatealgorithmsforfollow-upaftertreatment.

Options:Womenwithabnormalcytologyareatriskofdevelopingcervicalcancer;appropriatetriageandtreatmentwillreducethisrisk.

Outcomes:AqualityguidelinewillfacilitateimplementationofcommonstandardsacrossCanada,movingawayfromthecurrenttrendofindividualguidelinesineachprovinceandterritory.

Evidence:PublishedliteraturewasretrievedthroughsearchesofPubMedorMEDLINE,CINAHL,andTheCochraneLibraryinOctober2008usingappropriatecontrolledvocabulary(e.g.,colposcopy,cervicaldysplasia)andkeywords(e.g.,colposcopymanagement,CIN,AGC,cervicaldysplasia,LEEP,LLETZ,HPVtesting,cervicaldysplasiatriage).Resultswererestrictedtosystematicreviews,randomizedcontroltrials/controlledclinicaltrials,andobservationalstudies.Therewerenodateorlanguagerestrictions.SearcheswereupdatedonaregularbasisandincorporatedintheguidelinetoDecember2011.Grey(unpublished)literaturewasidentifiedthroughsearchingtheWebsitesofhealthtechnologyassessment(HTA)andHTA-relatedagencies,clinicalpracticeguidelinecollections,andfromnationalandinternationalmedicalspecialtysocieties.Expertopinionfrompublishedpeer-reviewedliteratureandevidencefromclinicaltrials(whereavailable)issummarized.Consensusopinionisoutlinedwhereevidenceisinsufficient.

Values:ThequalityoftheevidenceisratedusingthecriteriadescribedbytheCanadianTaskForceonPreventiveHealthCare(Table1).Thetaskforcehasrecentlyreconvenedandnonewrecommendationshavebeenreleased.

Benefits,HarmsandCosts:Theintentistopromotethebestpossiblecareforwomenwhileensuringefficientuseofavailableresources.

Validation:Thisguidelinehasbeenreviewedforaccuracyfromcontentexpertsin

3of34

cytology,pathologyandcervicalscreeningprograms.GuidelinecontentwasalsocomparedtosimilardocumentsfromotherorganizationsincludingtheAmericanSocietyforColposcopyandCervicalPathology,BritishSocietyforColposcopyandCervicalPathology,andtheEuropeanCancerNetwork.

Sponsors:None

KeyWords:CervicalCytology,CervicalCancer,Colposcopy,Treatment,Follow-up,Abnormalities,Guidelines

Recommendations

WaitTimesforColposcopy1. WomenwithHSILareideallyseeninacolposcopyclinicwithin4weeksof

referral.(III-C)

2. WomenwithASC-HorAGCshouldbeseeninacolposcopyclinicwithin6weeksofreferral.(III-C)

3. WomenwithaPaptestsuggestiveofcarcinomashouldbeseenwithin2weeksofreferral.(III-C)

4. Otherresultsshouldbeseeninacolposcopyclinicwithin8weeksofreferral.(III-C)

TheColposcopyExam1. Colposcopicfindingscanbedescribedaccordingtotheterminologydefined

bytheInternationalFederationforCervicalPathologyandColposcopy.(III-C)

2. Atcolposcopy,twoormorebiopsiesshouldbetaken.(I-A)

3. AnECCshouldbeperformedwhencolposcopyisunsatisfactory,withanAGCpapandinolderwomenwithhigh-gradecytology.(II-2B)

4. RoutineHR-HPVtestingforallcolposcopyreferralsisdiscouraged.(III-C)

ManagingwomenwithASCUSorLSILonreferraltoColposcopy1. Acolposcopicallyidentifiedlesionshouldbebiopsied.(III-C)

2. Ifnolesionisidentified,arandombiopsyofthetransformationzonecouldbeconsidered.(III-C)

ManagingASC-H1. AwomanwithanASC-HPaptestshouldhavecolposcopytoruleoutCIN2/3

and/orcancer.(II-2A)

2. WithanASC-HPaptest,thefindingofnegativecolposcopydoesnotautomaticallywarrantadiagnosticexcisionalprocedure.(III-B)

4of34

ManagingHSIL1. AllwomenwithanHSILtestresultshouldhavecolposcopy.(II-2A)

2. Intheabsenceofanidentifiablelesionatcolposcopyandunsatisfactorycolposcopy,adiagnosticexcisionalprocedureshouldbeperformed.(III-B)

ManagingAtypicalGlandularCytology(AGC-NOS,AGC-N,AIS)1. ThefindingofanAGCPaptestwarrantscolposcopy.(II-2A)

2. AnAGC-NPaptestwithoutanidentifiablelesionatcolposcopyshouldbefollowedwithadiagnosticexcisionalprocedure.(II-2A)

ManagingSCCandAdenocarcinoma1. Womenwithacytologicdiagnosissuggestiveofcarcinoma,withorwithouta

visiblelesion,shouldhavecolposcopy.(IIIA)

ManagingthePatientwithAbnormalHPVTestandNormalCytology1. WomenwhotestpositiveforHR-HPVandhavenegativecytologyshould

haverepeattestingat12months.PersistentpositiveHR-HPVtestswarrantcolposcopy.(IA)

ManagingAbnormalCytologyinPregnancy1. WomenwithanASCUSorLSILtestresultduringpregnancyshouldhave

repeattestingpostpregnancy.(III-B)

2. WomenwithHSIL,ASC-HorAGCshouldbereferredpromptlyforcolposcopyinpregnancy.(III-B)

3. ECCisnotrecommendedduringpregnancy.(III-B)

ManagingAbnormalCytologyintheAdolescent1. Screeningshouldnotbeinitiatedinwomenlessthan21yearsofage.(II-2A)

2. Ifscreeningisdone,andanASC-USorLSILresultisreported,cytologyshouldberepeatedinoneyear,withreferraltocolposcopyifalow-gradetestresultcontinuesfor24months.(III-B)

3. CytologyresultsofASC-H,HSIL,andAGCintheadolescentshouldbereferredtocolposcopy.(III-B)

ManagingHistologicalAbnormalities

ManagingCIN11. BiopsyprovenCIN1shouldbeobservedwithrepeatcolposcopyat12-month

intervals.Persistencebeyond24monthsmaybetreatedorobservedwithrepeatcytologyand/orcolposcopy.(II-1B)

2. Biopsy-provenCIN1afterHSILorAGCcytology,anexcisionalprocedureshouldbeconsidered.(III-B)

5of34

ManagingCIN2/31. CIN2or3shouldbetreated;excisionalproceduresarepreferredforCIN3.

(II-1A)

2. Womenwhohavepositivemarginsshouldhaveclosefollow-upwithretreatmentwithexcisionforpersistentdisease.(II-1B)

ManagingCIN2/3intheAdolescent1. CIN2intheadolescentpatientshouldbeobservedwithcolposcopyat6-

monthintervalsforupto24monthsbeforetreatment.(II-2B)

2. CIN3shouldbetreatedintheadolescentpatient.(III-B)

ManagingAdenocarcinomainSitu(AIS)1. IfAISisdiagnosed,treatmentneedstobedonewithadiagnosticexcisional

procedure,ortype3TZexcision.(II-2A)

2. Ifmarginsarepositiveafterdiagnosticexcisionalprocedure,asecondexcisionalprocedureshouldbeperformed.(II-2A)

3. IfaftertreatmentforAISawomanhasfinishedchildbearing,ahysterectomyshouldbeconsidered.(III-B)

4. IfAISisdiagnosedafterLEEPisperformedforCINinawomanwhohasnotcompletedherfamilyandmarginsarenegative,itisunnecessarytoperformafurtherdiagnosticexcisionalprocedure.(II-2A)

ManagingHistologicalAbnormalitiesDuringPregnancy1. IfCIN2orCIN3isdiagnosedduringpregnancy,treatmentshouldbedelayed

untilafterdelivery.(II-2A)

Follow-upPostTreatment1. Post-treatmentforCIN2or3:womenshouldbefollowedwithcytologyand

colposcopyat6monthintervalsfortwovisits,aslongasbothcytologyandanybiopsiesarenegative.(II-2B)

2. Post-treatmentforCIN2or3:HPVtestingat6or12monthscombinedwithcytology.IfbothcytologyandHPVtestingarenegative,returningtoannualorbiannualcytologyisareasonableoption.(II-2B)

ManagingHistologicalAbnormalitiesinHigh-RiskIndividuals1. Immunocompromisedwomenshouldbescreenedannuallybutnotwith

colposcopy.(II-2B)

2. Immunocompromisedwomenshouldbetreatedwithanexcisionalproceduretakingcaretominimizepositivemargins.(II-2B)

6of34

Table1:Keytoevidencestatementsandgradingofrecommendations,usingtherankingoftheCanadianTaskForceonPreventativeHealthCare

QualityofEvidenceAssessment* Classificationof

Recommendations‡

I: Evidenceobtainedfromatleastoneproperlyrandomizedcontrolledtrial

II-1: Evidencefromwell-designedcontrolledtrialswithoutrandomization

II-2: Evidencefromwell-designedcohort(prospectiveorretrospective)orcase-controlstudies,preferablyfrommorethanonecentreorresearchgroup

II-3: Evidenceobtainedfromcomparisonsbetweentimesorplaceswithorwithouttheintervention.Dramaticresultsinuncontrolledexperiments(suchastheresultsoftreatmentwithpenicillininthe1940s)couldalsobeincludedinthecategory

III: Opinionsofrespectedauthorities,basedonclinicalexperience,descriptivestudies,orreportsofexpertcommittees

A. Thereisgoodevidencetorecommendtheclinicalpreventiveaction

B. Thereisfairevidencetorecommendtheclinicalpreventiveaction

C. Theexistingevidenceisconflictinganddoesnotallowtomakearecommendationfororagainstuseoftheclinicalpreventiveaction;however,otherfactorsmayinfluencedecision-making

D. Thereisfairevidencetorecommendagainsttheclinicalpreventiveaction

E. Thereisgoodevidencetorecommendagainsttheclinicalpreventiveaction

L. Thereisinsufficientevidence(inquantityorquality)tomakearecommendation;however,otherfactorsmayinfluencedecision-making

*ThequalityofevidencereportedintheseguidelineshasbeenadaptedfromTheEvaluationofEvidencecriteriadescribedintheCanadianTaskForceonPreventiveHealthCare.

†RecommendationsincludedintheseguidelineshavebeenadaptedfromtheClassificationofrecommendationscriteriadescribedinTheCanadianTaskForceonPreventiveHealthCare.

IntroductionOverthelast30yearscervicalcancermorbidityandmortalityrateshavedroppedsignificantlyinCanada,fromapproximately30per100,000to7per100,000

7of34

women(1).Thischangehasbeenwidelyattributedtotheavailabilityofcervicalscreeningviacytologicsampling(2).

Colposcopyhasevolvedtoevaluatethosewithabnormalcytologyandprovideahistologicalsamplebybiopsy.Treatmentoflesionscanthenbeperformed,usuallypreservingfertilityandavoidingmajorsurgery(3)(Ch1,p6).Numerousjurisdictionshavedevelopedguidelines(4-8)forcolposcopy1andthesehavebeenreviewedindevelopingthisdocument.

CervicalcancerscreeningisorganizedwithineachprovinceandterritoryinCanada.ScreeningProgramsissuescreeningandfollow-uprecommendationsforabnormalscreeningresults,includingreferraltocolposcopy.ThediversityandstatusofcervicalscreeninginCanadahasbeensummarizedelsewhere(9).

Theageforinitialscreeninghasbeenre-evaluatedrecently.ThisreviewofscreeninginitiationwaspioneeredbytheAmericanSocietyofColposcopyandCervicalPathology(ASCCP),whichconvenedaconsensuspracticeimprovementconferenceinJune2009.StakeholdersfromtheUnitedStates(USA)andCanadawereincluded.Outcomesfromthismeetingincludedarecommendationtostartscreeningatage21(10).ThisrecommendationhasbeenincorporatedintonewguidelinesfromQuébec(11)andAlberta(12).

Canadiancolposcopicpracticeisuniqueinseveralways.Colposcopyisperformedpredominantlybygynecologistsinbothhospitalclinicsandprivateoffices.AccesstoHPVtestingiscurrentlylimitedoutsideofteachinghospitals.TheprimaryaimoftheseguidelinesistostandardizethecolposcopiccareprovidedforwomeninCanada.

MethodsTheseguidelinesweredevelopedthroughtheleadershipoftheSocietyofCanadianColposcopy.Inputwassolicitedfromvariousorganizationsincluding;SocietyofGynecologicOncologyofCanada(GOC);SocietyofObstetriciansandGynecologistsofCanada(SOGC);CanadianAssociationofPathologists(CAP);CanadianSocietyofCytopathology(CSC);and,representationfromprovincialscreeningprograms.Aface-to-facemeetingofcontributorswasheldinDecember2008forthefollowingpurpose.Relevantliteraturewasreviewed,includingguidelinesrelatedtocolposcopicmanagementofabnormalcytologyandhistology.Clinicalquestionsweredevelopedanddiscussed.Whereevidencewasincomplete,consensusopinionprevailed.Guidelinesexistbothasformallypublishedandweb-baseddocuments;themostcommonlyreferencedarethosepublishedbytheAmericanSocietyforColposcopyandCervicalPathology(ASCCP)formanagementofcytologicalandhistologicalabnormalities(13,14).

1GuidelinesfrombothwithinandoutsideCanadahavebeenreviewedandwillbereferenced,whereappropriate,throughoutthedocument.

8of34

TheBethesda2001classificationsystem(15)isthecytologicalterminologycommonlyusedinCanada;thisterminologywasusedheretorepresentcytologicaldiagnosesandCINterminologywasemployedforhistologicaldiagnoses.(SeealsoTable2)

ColposcopicManagementofCytologicalAbnormalitiesScreeningandcolposcopyrecommendationsvaryacrossprovincesandterritoriesandhavebeendocumentedelsewhere(9).Currentguidelinesforcolposcopicreferralscanbesummarizedasfollows:referraltocolposcopyisrecommendedforpersistentASCUS,persistentorincidentLSIL,ASC-H,HSIL,andAGC2aswellasforPapanicolaou(Pap)teststhatsuggestsquamousorglandularcarcinoma.HPVtestingisnotwidelyavailable;however,whenreflexHPVtestingshowsthepresenceofoncogenic(orhighrisk)HPV(HR-HPV)withASCUScytology,referraltocolposcopyisrecommended.

WaitTimesforColposcopyPatientswithabnormalscreeningtestsshouldbeseenincolposcopywithinareasonabletime,giventheriskofhigh-gradechangesandpsychologicalstressassociatedwithanabnormalcytologyresult(16).Becauseofthis,theSOGCwaittimesstatementrecommendscolposcopicassessmentwithin3weeksforHSILcytology;6–8weeksforASC-HorLSIL;and6weeksforanAGCcytologyresult(17)TheserecommendationsaresimilartotheUKrecommendationthat90%ofcaseswithhigh-gradecytologyshouldbeseenwithin4weeksand90%ofalltestsshouldbeseenwithin8weeksofreferral(7).

TheimportanceofguidelinestodirectreferraltimestocolposcopywasillustratedinanOntariopopulation-basedreview(18).ReferralswerereviewedforPaptestresultsofHSIL,AGCandASC-Hbetween2000and2006.WomenwithHSILresultswereseenincolposcopyatamediantimeof67days,AGC108daysandASC-H80days.Invasivediseaseofthelowergenitaltractwasdetectedin2.4%ofASC-Hcases,3%ofAGCand3.12%ofHSIL.Unfortunatelyinthispopulationtherewasa26%losstofollow-up,i.e.,womenwhodidnothavecolposcopywithin24months.

Itisrecognizedthattheseareguidelinesandmaybedifficulttoachieve;however,triageeffortsshouldensurethatthosewithmoresignificantcytologicabnormalitiesareseenfirst.

Recommendations:

1. WomenwithHSILareideallyseeninacolposcopyclinicwithin4weeksofreferral.(III-C)


2SeeTable2fordescriptionoftheseterms.

9of34



TheColposcopyExamColposcopyistheexaminationofthelowergenitaltractandcervixusingmagnificationfromacolposcopewithagoodlightsource.Thesquamo-columnarjunctionandtransformationzoneshouldbeidentified,determiningwhethertheexamissatisfactoryornot.Aceticacidisthenusedtoassessthesize,shape,marginandlocationofanyneoplasticlesion.ThesefindingscanthenbedescribedaccordingtothenomenclatureoftheInternationalFederationforCervicalPathologyandColposcopy(19).

Whenanylesionisidentified,recentevidencesupportsthepracticeoftakingatleasttwobiopsiestoimprovetheaccuracyofcolposcopy.Abiopsyshouldbetakenofthemostsevereareafoundoncolposcopicexamination,eithertoconfirmorruleoutmalignantlesions(20,21).AnalysisoftheALTSdatashowedthat,takingtwobiopsiesforalow-gradecytologyreferralatinitialcolposcopy,improvedthesensitivity(todetectCIN2orgreater)to81.8%,comparedto68.3%withonebiopsy(20).

ArecentreviewoftheutilityofendocervicalcurettagewaspublishedusingdatafromCalgary.Basedonover13,000examinations,theauthorsshowedthat99ECCspecimenshadtobetakentodetectoneadditionalcaseofCIN2orhighergradelesion.Thelargestbenefitwasinolderwomenreferredafterhigh-gradecytology(22).AnECCshouldthusbeperformedwithunsatisfactorycolposcopy,anAGCsmear,andinolderwomenwithhigh-gradecytology

Alowthresholdisrecommendedforundertakingabiopsy.Ifanylesionisseen,biopsyshouldbecompleted.Ifonlymetaplasiaisinquestion,abiopsyshouldbeconsidered.Unlessdictatedbytheappropriatealgorithm,thereisnoroleforroutineHR-HPVtestinginthecolposcopyclinic.

Recommendations:

1. ColposcopicfindingscanbedescribedaccordingtotheterminologydefinedbytheInternationalFederationforCervicalPathologyandColposcopy.(III-C)




10of34

ManagingwomenwithASCUSorLSILonreferraltoColposcopyManagementoflow-gradeabnormalitiesremainscontroversial.AlargerandomizedtrialintheUSAconcludedthatwomenwithLSILcytologyresultswerebestmanagedbyimmediatereferraltocolposcopy;itwasnotedthat83%werepositiveforHR-HPVandthusHPVtriagewouldnotbeeffective(23).ThesamestudyreportedthatwomenwithASCUSresults,butnegativeforHR-HPV,couldsafelybetriagedawayfromcolposcopy(23).ThisapproachrequiresavailabilityofreflexHPVtesting;unfortunately,thisisnotwidelyavailableinCanada.ArecentmulticenterstudyintheUKevaluatedthemanagementofsimilarlowgradecytology.Outcomesindicatedthatapolicyofimmediatecolposcopyledtoincreasedreferralstocolposcopywithnoclearbenefitandpotentialharm(24).

Withlow-gradelesions,colposcopyisdonetoruleoutpotentiallypre-malignantchangesi.e.,CIN2or3;ifthisisdetected,managementisundertakenaccordingtotheappropriateprotocol.Ameta-analysisreportedCIN2+ratesof10%andCIN3+of6%withanASCUSreferral(25,26).WithanLSILreferral,theratesofCIN2+are17%andCIN3+12%(27,28).IfCIN1isthehighestgradeidentifiedatcolposcopy,conservativemanagementisrecommended.Ifnolesionisidentifiedatcolposcopy,arandombiopsyatthetransformationzoneshouldbeconsidered.Asperconsensusopinion,ifnodysplasiaisidentifiedatcolposcopy,annualscreeningwiththereferringhealthcareproviderisrecommended,untilthreenegativePaptestshavebeenreported.Ifallcytologyisnegative,womenmaythenbefollowedevery2to3years,consistentwithprovincial/territorialguidelines.

Recommendations:

1. Acolposcopicallyidentifiedlesionshouldbebiopsied.(III-C)


ManagingASC-HWithanASC-HresultonthePaptest,significantpathologyistypicallyfoundinthemajorityofcases.Inastudyof517casesfromEdmonton,Alberta,CIN2orgreaterwasdetectedin70%ofcases(29).MostcaseswereCIN2;however,invasivecarcinomawasreportedin2.9%ofcasesandAISin1.7%(29).AsimilarOntariostudyshowedCIN2orgreaterin59.4%ofcaseswithastrongercorrelationinwomenyoungerthan40years(30).AllwomenwithASC-Hshouldhavecolposcopytoruleoutsignificantpathology.Ifcolposcopyisnegative,recommendationsincludecolposcopy,repeatcytologyand,ideally,HR-HPVtestingtwice,atsixmonthintervals,toavoidmissingasignificantlesion.Iftheserepeattestsarenegative,womenmayreturntoregularscreening,asperprovincial/territorialprotocol.ThefindingofASC-Hwithnegativecolposcopydoesnotwarrantaconebiopsyordiagnosticexcisionalprocedurefordiagnosticpurposes.

Recommendations:

11of34

1. AwomanwithanASC-HPaptestshouldhavecolposcopytoruleoutCIN2/3and/orcancer.(II-2A)


ManagingHSILTheriskofasignificantlesionishighwithHSILcytology.StudieshaveshownCIN2orgreaterin53-66%ofcaseswhencolposcopicbiopsiesaretaken,andupto90%ifanimmediateLEEPisperformed(31,32).Becauseofthishighrateofsignificanthigh-gradehistology,allwomenwithanHSILresultshouldhavecolposcopy.AvisualassessmentandLEEPapproachmaybeappropriateinsomecircumstances,butacolposcopicallydirectedbiopsyandtailoredtreatmentispreferred.

Ifalesionisnotdetectedatcolposcopy,andcolposcopyisnotsatisfactory,thenadiagnosticexcisionalprocedureshouldbedone.Thiscanbeachievedwithaconebiopsy,orLEEPusingalargeloop,orasecondendocervicalpass.However,ifnolesionwasdetected,andcolposcopywassatisfactory,combinedcolposcopyandcytologyisappropriateatsix-monthintervalsfortwovisits.Thissituationisrare.Amongwomenwhohavefinishedchildbearing,adiagnosticexcisionalprocedureshouldbeconsidered.

Recommendations:

1. AllwomenwithanHSILtestresultshouldhavecolposcopy.(II-2A)


ManagingAtypicalGlandularCytology(AGC-NOS,AGC-N,AIS)ThefindingofAGC-NOS,AGC-NorAISalwayswarrantspromptreferraltocolposcopyintheabsenceofothersymptomatology.Neoplasticlesionsotherthanfromthecervix,includingendometrium,ovaryandfallopiantube,havebeenidentifiedwithAGCcytology(33-35).InaCanadianreport456casesofAGCorAGUSwereidentifiedoutofadatabaseofover1millionPaptests(0.043%)(34).Onfinalhistology7%werefoundtohaveCIN1,36%CIN2or3,AISwasidentifiedin20%,carcinomaofthecervixin9%,andendometrialpathologyin29%,includingcarcinomaoftheendometriumin10%.ItshouldbenotedthatCINisconsistentlythemostfrequentfindingacrossmanystudies(33,34,36,37).ThishighrateofpathologyprecludesanyattempttotriageusingrepeatcytologyorHPVtesting.

ThediagnosisofAGC-Nisassociatedwithhigherratesofabnormalitiesandthus,intheabsenceofanabnormalityfoundbycolposcopy,adiagnosticexcisionalprocedureshouldbeperformed(38,39).Adiagnosticexcisionalprocedureincludesacoldknifeconebiopsy,laserconebiopsyandmayincludeaLEEPifthespecimenisofsufficientsize.Ahysterectomyisnotconsideredasadiagnosticexcisionalprocedure.Endocervicalcurettage(ECC)shouldbedoneinallwomen,andendometrialsamplingshouldbeperformedinwomenover35yearsorifthereisahistoryofabnormalbleeding,includinganovulation.

12of34

However,withAGC-NOScytologyandtheabsenceofanidentifiedlesion,womenarestillatriskofdevelopingalesion.Inthissituation,follow-upassessmenteverysixmonthsfortwoyearsincludesrepeatcytology,colposcopyandECC.IfHR-HPVtestingisavailableandwasdoneattheinitialcolposcopyvisit,womenwhotestnegativeforHR-HPVmayhaverepeatassessmentwithcolposcopy,cytology,ECCandHR-HPVtestingat12months.Ifalesionisidentified,treatmentisguidedbythespecificguideline.Ifacarcinomaisidentified,referralshouldbemadetoagynecologiconcologist.Ifallfollowupisnegativeaftertwoyears,routinecytologictestingmayberesumed.

Recommendations:

1. ThefindingofanAGCPaptestwarrantscolposcopy.(II-2A)


ManagingSCCandAdenocarcinomaWomenshouldbereferredpromptlytocolposcopyiftheirPaptestissuggestiveofcarcinoma,withorwithoutavisiblelesion.AssessmentshouldincludecolposcopyanddirectedbiopsywithconsiderationofECC.Ifnoabnormalityisdetected,adiagnosticexcisionalprocedureisrecommendedtoruleoutoccultcarcinoma.EndometrialbiopsyshouldalsobecontemplatedintheworkupofwomenwithadenocarcinomaonaPaptest.

Recommendation:

1. Womenwithacytologicdiagnosissuggestiveofcarcinoma,withorwithoutavisiblelesion,shouldhavecolposcopy.(IIIA)

ManagingthePatientwithAbnormalHPVTestandNormalCytologyForthosewomenwithASCUSandpositivereflexHR-HPV,womenshouldbereferredtocolposcopy.However,noprovincialguidelinesaddressmanagementofnegativecytologyfindingscombinedwithapositiveHR-HPVresult.

WomenwithnegativecytologyandpositiveHPVresultsshouldhaverepeatsofbothtestsaftertwelvemonths(40,41),withtheirprimaryhealthcareprovider.Ifbothtestsarenegativeat12months,womenshouldreturntoscreeningasperprovincial/territorialguidelines.Womenwithacytologicalabnormalityshouldbemanagedaccordingtothecytologicaldiagnosis.IfthereispersistentHR-HPVontwotestsoneyearapart,referraltocolposcopyisrecommendedtoruleoutthepossibilityofahigh-gradelesion.

Recommendation:

1. WomenwhotestpositiveforHR-HPVandhavenegativecytologyshouldhaverepeattestingat12months.PersistentpositiveHR-HPVtestswarrantcolposcopy.(I-A)

13of34

ManagingAbnormalCytologyinPregnancyTheindicationsforcolposcopyduringpregnancyareessentiallythesameasfornon-pregnantwomen.Ifalow-gradelesion(ASCUSorLSIL)isfoundduringpregnancy,thePaptestshouldberepeatedatleastsixweekspostpartum.Thispracticeissafeastherateofcancerinthisgroupisverylow(42).IfHSIL,ASC-HorAGCisfound,promptevaluationwithcolposcopyisessential.Ifcolposcopyisunsatisfactoryinthefirsttrimester,itshouldberepeatedafter20weeksgestationwhen,becauseofthephysiologicalchanges,thecervixevertsitselfandthesquamo-columnarjunctionmaybecomevisible.

IfCIN3orcarcinomaissuspected,biopsyisrecommended.Thereisevidencethatbiopsyinpregnancyisnotharmful(43).Womenwithhigh-gradedysplasiainpregnancyshouldbeseenbyanexperiencedcolposcopist.

Recommendations:

1. WomenwithanASCUSorLSILtestresultduringpregnancyshouldhaverepeattestingpostpregnancy.(III-B)



ManagingAbnormalCytologyintheAdolescentThereislittleevidencethatscreeningbycytologyinadolescents(lessthan21yearsold)isbeneficial.Theincidenceofcervicalcancerisverylow.SEERdatafromtheUSAshowedarateof0.1/100,000inwomen15-19yearsoldand1.6/100,000inwomen20-24yearsold,comparedto15.5/100,000inwomen40-45yearsold(44).AlthoughHPVinfectionandlow-gradePaptestsarecommoninthisagegroup,mostoftheseinfections,andrelatedcytologicalchanges,willresolvewithoutintervention(45,46).Screeningisinvasiveandcanhaveadversepsychologicalsequelaeespeciallyifitleadstocolposcopyreferral(10,47).

Ifthisscreeningleadstotreatment,treatmentbyLEEPcanlaterbeassociatedwithaslightlyincreasedriskofprematureruptureofmembranesandpretermdelivery(48,49).HPVvaccinationhasrecentlybeeninstitutedinCanadaandthehighefficacyagainstHPV16and18shouldlikelyresultinfewerhighgradelesionsneedingtreatment(50-54).ThiscollectiveevidencehasledtheAmericanCollegeofObstetricsandGynecology,aswellastheprovincesofAlbertaandQuébectorecommendanolderageforscreeninginitiation–until21yearsofage(11,12,55,56).

Amongwomenyoungerthan21years,ifaPaptesthasbeendoneandabnormalitiesaredetectedatscreening,managementshouldbeconservativetoavoidharm.Low-gradechanges,i.e.,ASC-USandLSILregressinupto93%ofcaseswithconservativemanagement.Thuswomenlessthan21yearswithASC-USandLSILresultsshouldhaverepeatcytologyinoneyearwithreferraltocolposcopyonlyifabnormalities

14of34

persistfor24months(10).Womenyoungerthan21years,withASC-H,HSIL,orAGCresults,shouldbereferredtocolposcopy.

Recommendations:

1. Screeningshouldnotbeinitiatedinwomenlessthan21yearsofage.(II-2A)



ManagingHistologicalAbnormalitiesOncealesionhasbeenidentifiedoncolposcopy,andbiopsycompleted,adecisionmustbemaderegardingmanagement.Theaimoftreatmentistoremoveapotentiallyprecancerouslesiontoavoiddevelopmentofcarcinoma.TheinitialclassificationofcervicalintraepithelialneoplasiaasCIN1,2or3wasproposedbyRichartin1973andsubsequentlyreinforcedbytheWorldHealthOrganizationin1994(57).TherateofprogressionofthesedysplasticlesionshasbeenwellreviewedbyOstor(58)(Table3),andovertimethetherapeuticapproachhasbeenadaptedtoavoidharmwhenlesserCINgradesareunlikelytoprogresstoinvasivecancer.

Treatmentmodalitiesincludeeitherexcisionalorablativeapproaches(cryotherapyorlaserablation).ThefavouredmethodinCanadaisexcisional-theloopelectrosurgicalexcisionprocedure(LEEP).Althoughrelativelyeasytoperformintheoutpatientsetting,therecanbecomplications.Arecentmeta-analysisestimatedthat,afteraLEEPprocedure,theriskforpretermdeliveryinasubsequentpregnancyoflessthan32-34weeksgestation,was1in143treatments(48).Thesameresearchgroupsuggestedthatadepththresholdof10mmisalsoavariableinreducingharm.Consequently,ifthecolposcopistisabletoadjusttheproceduretothelesion,futurenegativesequelaeinpregnancymaybeminimized(59).

Treatmentistailoredtothelesionidentifiedonthecervix,byeitherremovingorablatingtheentiretransformationzone.TheInternationalFederationofCervicalPathologyandColposcopy(IFCPC)hasclassifiedthetransformationzone(TZ)intothreecategories(60).Atype1TZiscompletelyectocervical,andfullyvisible.Atype2TZisfullyvisible,hasanendocervicalcomponentandmayhaveanectocervicalcomponent.Atype3TZispredominantlyendocervical,notfullyvisibleandmayhaveanectocervicalcomponent(Figure1).

Usingthisclassification,ablativemethodscanbeusedforatype1or2TZifrecognizedcriteriaaremet(Table4).IfexcisionwithLEEPisutilizedthesizeofloopelectrodemustbeadjusteddependingonthelesion,i.e.,atype2TZrequiresalargerloopelectrodethanatype1TZtoensurethelesionisfullyexcised.Ifthelesionisnotseeninitsentirety,colposcopyisunsatisfactoryandablativetherapiesshouldnotbeused(60,61).Careshouldbetakentoavoidremovalofexcessive

15of34

cervicalstromawhichwouldpredisposewomentopretermdelivery,especiallyifusingverylargeloopsortakingmultiplepasses.

Atype3TZwithalesionthatextendsintotheendocervicalcanal,oraglandularlesion,requiresalargerorlongerexcisionforadequateevaluationortreatment.ThisdocumentadoptedthenewIFCPCterminologytoidentifythisprocedureasatype3excisiontoavoidthecurrentconfusioninterminology(62).Currently,conebiopsy,diagnosticexcisionalprocedure,laserexcisionandLEEPmaybeusedbuthavedifferentmeaningstoindividualcolposcopists(61).

ManagingCIN1EvidencefromtherecentALTStrialhasconfirmedsignificantinter-observervariabilityinthehistologicaldiagnosisofCIN1,withtheoverlapoftenobservedwithbenignHPVinfection(63).OurcurrentunderstandingisthatCIN1seldomprogressestoinvasivediseaseandthatitwillregresswithouttreatmentwithin2-5yearsin60-80%ofallcases(58,64).Regressionratesareevenmorepronouncedinadolescents,withregressionoflow-gradesquamousintra-epitheliallesionsinupto91%ofcasesoverathree-yearperiod(65).ThisknowledgehasledtoachangeinthetreatmentphilosophyforCIN1.

ConservativemanagementwithobservationispreferredforCIN1.Womenshouldbefollowedwithrepeatcytologyandcolposcopyat12-monthintervals;ifnolesionisidentifiedshemayreturntoroutinescreening.Ifthelesionpersistsfor24monthsorlonger,treatmentisacceptable.Ifcolposcopyissatisfactory,treatmentmaybebyablativemodalities.Howeverinacompliantpatient,longerfollow-upispossible,especiallyinwomenwhohavenotcompletedchildbearing.

TheexceptiontoaconservativeapproachoccurswhenadiagnosisofCIN1isprecededbyHSILorAGCcytology.Inthesesituations,histologicalfindingshavenotadequatelyexplainedtheabnormalcytologyandanexcisionalprocedureshouldbeconsidered.

Recommendations:

1. BiopsyprovenCIN1shouldbeobservedwithrepeatcolposcopyat12-monthintervals.Persistencebeyond24monthsmaybetreatedorobservedwithrepeatcytologyand/orcolposcopy.(II-1B)


ManagingCIN2/3PathologicallyconfirmedhighgradedysplasiaincludesCIN2andCIN3,thesearetreatedinthesamefashioninmostjurisdictions(7,13,66-69).Therearehoweverdifferencesintheratesofregression.TheclassicalreviewbyOstorshowedthatCIN2regressesin43%andprogressedtoCIN3+in27%thiscomparestoregressionof33%persistenceof52%andprogressiontoinvasioninatleast12%ofCIN3cases(58).(SeeTable3.)ThetruemalignantpotentialofCIN3hasbeendemonstratedinNewZealandbylong-termfollow-upofCIN3thatwasnottreated.Thisshowedthat

16of34

theinvasiveriskinuntreatedCIN3is31%over30years,alsonotingthatpatientswithdocumentedpersistentCIN3for2yearshadariskofsubsequentinvasionof50%(70).

ForthesereasonsmostwomenwithCIN2or3shouldbetreated3.Ifcolposcopyissatisfactory,i.e.,atype1or2TZ,excisionandablativetherapyarebothacceptable;however,anexcisionalprocedureispreferredforthetreatmentofCIN3.IfCIN2or3isidentifiedandcolposcopyisunsatisfactory,anexcisionalprocedureshouldbeperformed.Ifattreatment,marginsarepositiveforCIN,ortheECC(ifdone)ispositive,thesewomenareatincreasedriskofpersistentdysplasia.Inameta-analysisofexcisionaltreatment,theriskofpost-treatmentdiseasewas18%forincompleteexcisionand3%forcompleteexcision(71).Ifthedeepmarginsareinvolved,considerationshouldbemadeforrepeatexcision.Mostwomenshouldbefollowedwithrepeatcolposcopyat6months(72).HysterectomyisnotrecommendedasinitialtherapyforCIN2or3butmaybeperformedforwomenwithpersistentCIN.

Recommendations:

1. CIN2or3shouldbetreated;excisionalproceduresarepreferredforCIN3.(II-1A)

2. Womenwhohavepositivemarginsshouldhaveclosefollow-upwithretreatmentwithexcisionforpersistentdisease.(BII-1B)

ManagingCIN2/3intheAdolescentAsdiscussedearlierthereislittleevidencetojustifyroutinescreeningintheadolescentpatient.Ifhowever,Papscreeningiscompleted,thesepatientsmaybereferredforcolposcopy.Managementmustbemodifiedtoavoidharm.RecentevidencesuggeststhatregressionofCIN2inthispopulationoccursataratesimilartoCIN1(10,46,73,74).

Basedontheevidence,thisgroup’sconsensusopinionisthatCIN2intheadolescentcanbeobservedwithrepeatcolposcopyandcytologyevery6monthsforupto24months.Ifdysplasiapersiststhepatientshouldbetreated,eitherwithablativemethodsoraLEEP.Thisisconditionalonasatisfactorycolposcopy;ifitisunsatisfactory,treatmentshouldbeperformedwithanexcisionalprocedure.ArecentstudylookedatregressionratesofCIN2inwomenlessthan25yearsold,mostwere20-25yearsold,theoverallregressionrateoveramedianof8monthswas62%.Thissuggeststhatobservationmaybereasonableinyoungwomenlessthan25yearsold(20).Insomecenters,high-gradehistologyisdesignatedasHSIL,i.e.,CINterminologyisnotused.IfthebiopsyisreportedasHSILinanadolescentwomanwesuggestareviewofthehistologyusingCINterminology.IfreclassifiedasCIN3,treatmentbyanexcisionalmethodispreferred.

3Remainingwomen–thosewhoareyoungerorpregnant–aremanagedasoutlinedelsewhereinthisdocument.

17of34

Recommendations:

1. CIN2intheadolescentpatientshouldbeobservedwithcolposcopyat6-monthintervalsforupto24monthsbeforetreatment.(II-2B)


ManagingAdenocarcinomainSitu(AIS)InCanadatheratioofadenocarcinomatosquamouscarcinomaofthecervixisincreasing;adenocarcinomacomprises20-25%ofallcervicalcancer(75).ThisislargelyafunctionofasignificantdecreaseinsquamouscellcancersduetowidespreadavailabilityofscreeningbyPaptestsoverseveraldecades.Nevertheless,implementationofcytologyqualityassuranceinitiativesinrecentyearshasbeenassociatedwithadecreaseinadenocarcinomaofthecervix.

Incontrast,diagnosisofpremalignantadenocarcinomainsitu(AIS)occursataratioof1:50,whencomparedwithseveresquamousdysplasia(76).ConsequentlyacolposcopistwillnotoftenseeAISandthetreatmentremainscontroversial.Colposcopicfeaturescanbedifficulttoidentifyandlesionsoftenextendhighinthecanal(77).Bertrandandcolleaguesshowedthatin78%ofcasesthehighestlesioninthecanalwaslessthan20mmfromtheexocervixandnonewerehigherthan29.9mm(78).Subsequenttoadiagnosisofadenocarcinomainsitueitheronpunchbiopsyorendocervicalcurretage,adiagnosticexcisionalprocedure,ortype3TZexcisionshouldbeperformed.Marginstatusisanimportantpredictorofresidualdisease,andthusthemethodchosenfortreatmentmustpreservetheabilitytoassesstheendocervicalmargin.Arecentmeta-analysisof33studiesshowedthattheriskofresidualdiseasewas2.6%withnegativemarginsand19.4%withpositivemargins.Invasivecarcinomawasalsomorefrequentlyassociatedwithpositivemargins(5.2%)comparedwithnegativemargins(0.1%)(79).Thus,ifmarginsarepositive,asecondexcisionisrequired.

IfAISisdiagnosedaftercompletingaLEEPprocedure(becauseofaCINfinding),themarginsneedtobecarefullyexamined.IftheAISissmallandmarginsareclear,thereisnoneedtoperformanexcisionalprocedureunlesschildbearingiscomplete,whenhysterectomyshouldbeconsidered(80).

Iffertilityisnotanissueoronecannotachievenegativemargins,ahysterectomyisrecommended(79).

AftertreatmentforAIS,ifthewomanwishestopreserveherfertility,shecanbecloselyobservedinthecolposcopyclinic.Sheshouldbeseenforcolposcopy,ECCandcytologyevery6to12months,foratleast5years.HR-HPVtestingcanbeutilizedtoaidreassurance.Thereafterthepatientshouldhaveannualcytology.

Recommendations:

1. IfAISisdiagnosed,treatmentneedstobedonewithadiagnosticexcisionalprocedure,ortype3TZexcision.(II-2A)

18of34




ManagingHistologicalAbnormalitiesDuringPregnancyTheaimofcolposcopyinpregnancyistoruleoutadiagnosisofinvasiveormicro-invasivecarcinoma.Ifdiagnosed,thesecasesshouldbepromptlyreferredtoagynecologiconcologist.IfCIN2orCIN3isdiagnosedduringpregnancy,theavailableevidencewouldsuggestthattreatmentcanbedelayeduntilafterdelivery.TheriskofprogressionisnotaffectedbythepregnancyandregressiontoCIN1ornormalpostpregnancyisbetween31and47%(81,82).

Recommendations:

1. IfCIN2orCIN3isdiagnosedduringpregnancy,treatmentshouldbedelayeduntilafterdelivery.(II-2A)

Follow-upPostTreatmentOncetreatedforCINorAIS,awomanremainsatriskofpersistenceorrecurrenceandatlong-termriskofinvasivecarcinoma(13,83,84).FailureratesfollowingtreatmentforCINdonotvarysignificantlywiththetreatmentmethodusedandinpublishedseriesarebetween5%and13%(85,86).Theaimoffollow-upistodetectpersistentorrecurrentdysplasia.

ConventionallyinCanada,womenarefollowedaftertreatmentwithcolposcopyandcytologyat6monthintervalsfor1to2years,priortoreturningtocytologyonanannualbasiswiththeirprimaryhealthcareprovider.InrecentyearstheavailabilityofHR-HPVtestinghasraisedthepossibilityofitsusetofollowwomenandpotentiallydetectrecurrenceorpersistenceearlier.Reviewsandmeta-analyseshaveevaluatedthisapproachanddemonstratethatHPVtestingmaybemoresensitivefordetectingrecurrence(87-91).Ithasbeennotedthatanadequatelypoweredprospectivetrialisneededtotrulyevaluatethisissue(91,92).SuchatrialisunderwayinseveralCanadiancenters(93).

Recommendations:

1. Post-treatmentforCIN2or3:womenshouldbefollowedwithcytologyandcolposcopyat6monthintervalsfortwovisits,aslongasbothcytologyandanybiopsiesarenegative.(II-2B)


19of34

ManagingHistologicalAbnormalitiesinHigh-RiskIndividualsNumerousmedicalconditionsreportedlyaffecttheabilitytolimitprogressionofHPVinfectiontodysplasia,andhenceareassociatedwithdysplasia.Theseincludetransplantationwithassociatedimmunosuppression,medicationforconditionssuchasCrohn'sDisease,rheumatoidarthritis,diabetesorHIVinfection.MostavailableinformationrelatestotransplantandHIVpatients.Inareviewfrom1995,144womenwerefollowedafterrenaltransplant.Therewasa17.5%incidenceofdysplasia(94).Similaroutcomeswerereportedafterlivertransplantaswellas13%incidenceofHSIL(95).ThelinkbetweencervicalcancerandHIViswelldocumented.Therateofcervicalcancerisupto4-6timeshigherinHIV-positivewomen(96).Inrecentyearsimprovedsurvivalhasbeenattributedtotheavailabilityofhighlyactiveantiretroviraltherapy(HAART)(96).Inareviewof400womenwhowereHIV-positiveinCapeTown,high-riskHPVwaspresentin68%ofthesewomenand55%hadabnormalPapsmears.MostPaptestresultswerelow-gradechanges,ofwhichonly4%progressed,13%wereHSIL(97).InonereviewfromNorthAmericatheratesofCIN2+withanASCUS/LSILreferralwere13.3%inHIV-negativewomenand15.3inHIV-positivewomen(98).ThereisnogoodevidencetorecommendroutinecolposcopyinthisgroupandtheycanbescreenedwithannualPaptests(99).IfatcolposcopyCIN1isdiagnosedthesewomencanbeobservedandtreatedforpersistentdisease.CIN2/3needtobetreatedandexcisionalmethodsarepreferred.Thereisahighrateofrecurrencethusawideexcisionshouldbeused(100).HAARTtherapyseemstodecreaserecurrence.Recommendations:

1. Immunocompromisedwomenshouldbescreenedannuallybutnotwithcolposcopy.(II-2B)


Recommendations

WaitTimesforColposcopy5. WomenwithHSILareideallyseeninacolposcopyclinicwithin4weeksof

referral.(III-C)



20of34


TheColposcopyExam5. Colposcopicfindingscanbedescribedaccordingtotheterminologydefined

bytheInternationalFederationforCervicalPathologyandColposcopy.(III-C)




ManagingwomenwithASCUSorLSILonreferraltoColposcopy3. Acolposcopicallyidentifiedlesionshouldbebiopsied.(III-C)


ManagingASC-H3. AwomanwithanASC-HPaptestshouldhavecolposcopytoruleoutCIN2/3

and/orcancer.(II-2A)


ManagingHSIL3. AllwomenwithanHSILtestresultshouldhavecolposcopy.(II-2A)


ManagingAtypicalGlandularCytology(AGC-NOS,AGC-N,AIS)3. ThefindingofanAGCPaptestwarrantscolposcopy.(II-2A)


ManagingSCCandAdenocarcinoma2. Womenwithacytologicdiagnosissuggestiveofcarcinoma,withorwithouta

visiblelesion,shouldhavecolposcopy.(IIIA)

ManagingthePatientwithAbnormalHPVTestandNormalCytology2. WomenwhotestpositiveforHR-HPVandhavenegativecytologyshould

haverepeattestingat12months.PersistentpositiveHR-HPVtestswarrantcolposcopy.(IA)

21of34

ManagingAbnormalCytologyinPregnancy4. WomenwithanASCUSorLSILtestresultduringpregnancyshouldhave

repeattestingpostpregnancy.(III-B)



ManagingAbnormalCytologyintheAdolescent4. Screeningshouldnotbeinitiatedinwomenlessthan21yearsofage.(II-2A)



ManagingHistologicalAbnormalities

ManagingCIN13. BiopsyprovenCIN1shouldbeobservedwithrepeatcolposcopyat12-month

intervals.Persistencebeyond24monthsmaybetreatedorobservedwithrepeatcytologyand/orcolposcopy.(II-1B)


ManagingCIN2/33. CIN2or3shouldbetreated;excisionalproceduresarepreferredforCIN3.

(II-1A)

4. Womenwhohavepositivemarginsshouldhaveclosefollow-upwithretreatmentwithexcisionforpersistentdisease.(II-1B)

ManagingCIN2/3intheAdolescent3. CIN2intheadolescentpatientshouldbeobservedwithcolposcopyat6-

monthintervalsforupto24monthsbeforetreatment.(II-2B)


ManagingAdenocarcinomainSitu(AIS)5. IfAISisdiagnosed,treatmentneedstobedonewithadiagnosticexcisional

procedure,ortype3TZexcision.(II-2A)



22of34


ManagingHistologicalAbnormalitiesDuringPregnancy2. IfCIN2orCIN3isdiagnosedduringpregnancy,treatmentshouldbedelayed

untilafterdelivery.(II-2A)

Follow-upPostTreatment3. Post-treatmentforCIN2or3:womenshouldbefollowedwithcytologyand

colposcopyat6monthintervalsfortwovisits,aslongasbothcytologyandanybiopsiesarenegative.(II-2B)


ManagingHistologicalAbnormalitiesinHigh-RiskIndividuals3. Immunocompromisedwomenshouldbescreenedannuallybutnotwith

colposcopy.(II-2B)


References

(1)CanadianCancerSociety'sSteeringCommittee.CanadianCancerStatistics.2009.

(2)InternationalAgencyforResearchonCancer,WorldHealthOrganization.IARCHandbooksofCancerPrevention:CervixCancerScreening.Lyon:IARCPress;2005.

(3)FerrisDG,CoxJT,O'ConnorDM,WrightVC,FoersterJ.ModernColposcopyTextbookandAtlas.:Kendall/HuntPublishingCompany;2004.

(4)WorkingGroupofCervicalScreenSingapore.ManagementGuidelinesforAbnormalPapSmear&InvasiveDiseaseoftheCervix.2002.

(5)AustralianNationalHealthandMedicalResearchCouncil.Screeningtopreventcervicalcancer:guidelinesforthemanagementofasymptomaticwomenwithscreendetectedabnormalities.2005.

(6)WrightTC,Jr,MassadLS,DuntonCJ,SpitzerM,WilkinsonEJ,SolomonD,etal.2006ConsensusGuidelinesfortheManagementofWomenwithCervicalIntraepithelialNeoplasiaOrAdenocarcinomainSitu.JLowGenitTractDis2007Oct;11(4):223-239.

(7)NationalHealthService.ColposcopyandProgrammeManagement:GuidelinesfortheNHSCervicalScreeningProgramme,2ndEdition.2010;Availableat:

23of34

http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.html.Accessed02/28,2011.

(8)ArbynM,AnttilaA,JordanJ,RoncoG,SchenckU,SegnanN,etal.EuropeanGuidelinesforQualityAssuranceinCervicalCancerScreening.Secondedition--summarydocument.AnnOncol2010Mar;21(3):448-458.

(9)MurphyKJ,HowlettRI.ScreeningforCervicalCancer.JOGC2007;29(8):S27-S36.

(10)MoscickiAB,CoxJT.Practiceimprovementincervicalscreeningandmanagement(PICSM):symposiumonmanagementofcervicalabnormalitiesinadolescentsandyoungwomen.JLowGenitTractDis2010Jan;14(1):73-80.

(11)InstitutnationaledesantepubliqueQuebec.RecommendationsonoptimizingcervicalcancerscreeninginQuébec.2009;Availableat:http://www.inspq.qc.ca/pdf/publications/1081_CervicalScreening.pdf.Accessed03/11,2011.

(12)AlbertaHealthServices.AlbertaCervicalCancerScreening:ClinicalPracticeGuidelinesandManagementofAbnormalCytology.2009;Availableat:http://www.screeningforlife.ca/_files/file.php?fileid=filenrNvasUkRV&filename=file_CC_CPG_Summary_Chart_LowR_Mar_2010.pdf.Accessed03/11,2011.

(13)WrightTC,Jr,MassadLS,DuntonCJ,SpitzerM,WilkinsonEJ,SolomonD,etal.2006ConsensusGuidelinesfortheManagementofWomenwithAbnormalCervicalCancerScreeningTests.AmJObstetGynecol2007Oct;197(4):346-355.

(14)WrightTC,Jr,MassadLS,DuntonCJ,SpitzerM,WilkinsonEJ,SolomonD,etal.2006ConsensusGuidelinesfortheManagementofWomenwithCervicalIntraepithelialNeoplasiaOrAdenocarcinomainSitu.AmJObstetGynecol2007Oct;197(4):340-345.

(15)SolomonD,DaveyD,KurmanR,MoriartyA,O'ConnorD,PreyM,etal.The2001BethesdaSystem:terminologyforreportingresultsofcervicalcytology.JAMA2002Apr24;287(16):2114-2119.

(16)LeT,HopkinsL,MenardC,Hicks-BoucherW,LefebvreJ,FungKeeFungM.Psychologicmorbiditiespriortoloopelectrosurgicalexcisionprocedureinthetreatmentofcervicalintraepithelialneoplasia.IntJGynecolCancer2006May-Jun;16(3):1089-1093.

(17)FarrellS,RoyeC,CraneJ,DavisD,HeywoodM,LalondeA,etal.Statementonwaittimesinobstetricsandgynaecology.JObstetGynaecolCan2008Mar;30(3):248-270.

(18)KupetsR,PaszatL.HowarewomenwithhighgradePapsmearabnormalitiesmanaged?Apopulationbasedstudy.GynecolOncol2011Jun1;121(3):499-504.

(19)WalkerP,DexeusS,DePaloG,BarrassoR,CampionM,GirardiF,etal.Internationalterminologyofcolposcopy:anupdatedreportfromtheInternational

24of34

FederationforCervicalPathologyandColposcopy.ObstetGynecol2003Jan;101(1):175-177.

(20)GageJC,HansonVW,AbbeyK,DipperyS,GardnerS,KubotaJ,etal.Numberofcervicalbiopsiesandsensitivityofcolposcopy.ObstetGynecol2006Aug;108(2):264-272.

(21)ZuchnaC,HagerM,TringlerB,GeorgoulopoulosA,Ciresa-KoenigA,VolggerB,etal.Diagnosticaccuracyofguidedcervicalbiopsies:aprospectivemulticenterstudycomparingthehistopathologyofsimultaneousbiopsyandconespecimen.AmJObstetGynecol2010Oct;203(4):321.e1-321.e6.

(22)GageJC,DugganMA,NationJG,GaoS,CastlePE.Detectionofcervicalcanceranditsprecursorsbyendocervicalcurettagein13,115colposcopicallyguidedbiopsyexaminations.AmJObstetGynecol2010Aug26.

(23)ASCUS-LSILTriageStudy(ALTS)Group.Arandomizedtrialonthemanagementoflow-gradesquamousintraepitheliallesioncytologyinterpretations.AmJObstetGynecol2003Jun;188(6):1393-1400.

(24)TOMBOLAGroup.Cytologicalsurveillancecomparedwithimmediatereferralforcolposcopyinmanagementofwomenwithlowgradecervicalabnormalities:multicentrerandomisedcontrolledtrial.BMJ2009Jul28;339:b2546.

(25)ArbynM,DillnerJ,VanRanstM,BuntinxF,Martin-HirschP,ParaskevaidisE.Re:Haveweresolvedhowtotriageequivocalcervicalcytology?JNatlCancerInst2004Sep15;96(18):1401-2;authorreply1402.

(26)ArbynM,BuntinxF,VanRanstM,ParaskevaidisE,Martin-HirschP,DillnerJ.VirologicversuscytologictriageofwomenwithequivocalPapsmears:ameta-analysisoftheaccuracytodetecthigh-gradeintraepithelialneoplasia.JNatlCancerInst2004Feb18;96(4):280-293.

(27)ArbynM,ParaskevaidisE,Martin-HirschP,PrendivilleW,DillnerJ.ClinicalutilityofHPV-DNAdetection:triageofminorcervicallesions,follow-upofwomentreatedforhigh-gradeCIN:anupdateofpooledevidence.GynecolOncol2005Dec;99(3Suppl1):S7-11.

(28)ArbynM,SasieniP,MeijerCJ,ClavelC,KoliopoulosG,DillnerJ.Chapter9:ClinicalapplicationsofHPVtesting:asummaryofmeta-analyses.Vaccine2006Aug31;24Suppl3:S3/78-89.

(29)BarrethD,SchepanskyA,CapstickV,JohnsonG,SteedH,FaughtW.Atypicalsquamouscells-cannotexcludehigh-gradesquamousintraepitheliallesion(ASC-H):aresultnottobeignored.JObstetGynaecolCan2006Dec;28(12):1095-1098.

(30)MokhtarGA,DelatourNL,AssiriAH,GilliattMA,SentermanM,IslamS.Atypicalsquamouscells,cannotexcludehigh-gradesquamousintraepitheliallesion:

25of34

cytohistologiccorrelationstudywithdiagnosticpitfalls.ActaCytol2008Mar-Apr;52(2):169-177.

(31)MassadLS,CollinsYC,MeyerPM.BiopsycorrelatesofabnormalcervicalcytologyclassifiedusingtheBethesdasystem.GynecolOncol2001Sep;82(3):516-522.

(32)DunnTS,BurkeM,ShwayderJ.A"seeandtreat"managementforhigh-gradesquamousintraepitheliallesionpapsmears.JLowGenitTractDis2003Apr;7(2):104-106.

(33)TamKF,CheungAN,LiuKL,NgTY,PunTC,ChanYM,etal.Aretrospectivereviewonatypicalglandularcellsofundeterminedsignificance(AGUS)usingtheBethesda2001classification.GynecolOncol2003Dec;91(3):603-607.

(34)DanielA,BarrethD,SchepanskyA,JohnsonG,CapstickV,FaughtW.Histologicandclinicalsignificanceofatypicalglandularcellsonpapsmears.IntJGynaecolObstet2005Dec;91(3):238-242.

(35)CastlePE,FettermanB,PoitrasN,LoreyT,ShaberR,KinneyW.Relationshipofatypicalglandularcellcytology,age,andhumanpapillomavirusdetectiontocervicalandendometrialcancerrisks.ObstetGynecol2010Feb;115(2Pt1):243-248.

(36)ZhaoC,FloreaA,OniskoA,AustinRM.Histologicfollow-upresultsin662patientswithPaptestfindingsofatypicalglandularcells:resultsfromalargeacademicwomenshospitallaboratoryemployingsensitivescreeningmethods.GynecolOncol2009Sep;114(3):383-389.

(37)CastlePE,FettermanB,PoitrasN,LoreyT,ShaberR,KinneyW.Relationshipofatypicalglandularcellcytology,age,andhumanpapillomavirusdetectiontocervicalandendometrialcancerrisks.ObstetGynecol2010Feb;115(2Pt1):243-248.

(38)SchnatzPF,GuileM,O'SullivanDM,SoroskyJI.Clinicalsignificanceofatypicalglandularcellsoncervicalcytology.ObstetGynecol2006Mar;107(3):701-708.

(39)UllalA,RobertsM,BulmerJN,MathersME,WadehraV.Theroleofcervicalcytologyandcolposcopyindetectingcervicalglandularneoplasia.Cytopathology2009Dec;20(6):359-366.

(40)CuzickJ,SzarewskiA,CubieH,HulmanG,KitchenerH,LuesleyD,etal.Managementofwomenwhotestpositiveforhigh-risktypesofhumanpapillomavirus:theHARTstudy.Lancet2003Dec6;362(9399):1871-1876.

(41)CastlePE,FettermanB,ThomasCoxJ,ShaberR,PoitrasN,LoreyT,etal.Theage-specificrelationshipsofabnormalcytologyandhumanpapillomavirusDNAresultstotheriskofcervicalprecancerandcancer.ObstetGynecol2010Jul;116(1):76-84.

26of34

(42)WettaLA,MatthewsKS,KemperML,WhitworthJM,FainET,HuhWK,etal.Themanagementofcervicalintraepithelialneoplasiaduringpregnancy:iscolposcopynecessary?JLowGenitTractDis2009Jul;13(3):182-185.

(43)KohanS,BeckmanEM,BigelowB,KleinSA,DouglasGW.Theroleofcolposcopyinthemanagementofcervicalintraepithelialneoplasiaduringpregnancyandpostpartum.JReprodMed1980Nov;25(5):279-284.

(44)RiesL,MelbertD,Krapcho,M.(eds.),etal.SEERCancerStatisticsReview,1975-2004.2007.

(45)MountSL,PapilloJL.Astudyof10,296pediatricandadolescentPapanicolaousmeardiagnosesinnorthernNewEngland.Pediatrics1999Mar;103(3):539-545.

(46)MoscickiAB,MaY,WibbelsmanC,DarraghTM,PowersA,FarhatS,etal.Rateofandrisksforregressionofcervicalintraepithelialneoplasia2inadolescentsandyoungwomen.ObstetGynecol2010Dec;116(6):1373-1380.

(47)LeT,HopkinsL,MenardC,Hicks-BoucherW,LefebvreJ,FungKeeFungM.Psychologicmorbiditiespriortoloopelectrosurgicalexcisionprocedureinthetreatmentofcervicalintraepithelialneoplasia.IntJGynecolCancer2006May-Jun;16(3):1089-1093.

(48)ArbynM,KyrgiouM,SimoensC,RaifuAO,KoliopoulosG,Martin-HirschP,etal.Perinatalmortalityandothersevereadversepregnancyoutcomesassociatedwithtreatmentofcervicalintraepithelialneoplasia:meta-analysis.BMJ2008Sep18;337:a1284.

(49)SamsonSL,BentleyJR,FaheyTJ,McKayDJ,GillGH.Theeffectofloopelectrosurgicalexcisionprocedureonfuturepregnancyoutcome.ObstetGynecol2005Feb;105(2):325-332.

(50)FUTUREIIStudyGroup.Quadrivalentvaccineagainsthumanpapillomavirustopreventhigh-gradecervicallesions.NEnglJMed2007May10;356(19):1915-1927.

(51)KohliM,FerkoN,MartinA,FrancoEL,JenkinsD,GallivanS,etal.Estimatingthelong-termimpactofaprophylactichumanpapillomavirus16/18vaccineontheburdenofcervicalcancerintheUK.BrJCancer2007Jan15;96(1):143-150.

(52)CuttsFT,FranceschiS,GoldieS,CastellsagueX,deSanjoseS,GarnettG,etal.HumanpapillomavirusandHPVvaccines:areview.BullWorldHealthOrgan2007Sep;85(9):719-726.

(53)RogozaRM,FerkoN,BentleyJ,MeijerCJ,BerkhofJ,WangKL,etal.Optimizationofprimaryandsecondarycervicalcancerpreventionstrategiesinaneraofcervicalcancervaccination:amulti-regionalhealtheconomicanalysis.Vaccine2008Sep15;26Suppl5:F46-58.

(54)PaavonenJ,NaudP,SalmeronJ,WheelerCM,ChowSN,ApterD,etal.Efficacyofhumanpapillomavirus(HPV)-16/18AS04-adjuvantedvaccineagainstcervical

27of34

infectionandprecancercausedbyoncogenicHPVtypes(PATRICIA):finalanalysisofadouble-blind,randomisedstudyinyoungwomen.Lancet2009Jul25;374(9686):301-314.

(55)ACOGCommitteeonGynecologicalPractice.ACOGcommitteeopinionNo.431:routinepelvicexaminationandcervicalcytologyscreening.ObstetGynecol2009May;113(5):1190-1193.

(56)ACOGCommitteeonPracticeBulletins--Gynecology.ACOGPracticeBulletinno.109:Cervicalcytologyscreening.ObstetGynecol2009Dec;114(6):1409-1420.

(57)ScullyRE.Histologicaltypingoffemalegenitaltracttumours1994:189.

(58)OstorAG.Naturalhistoryofcervicalintraepithelialneoplasia:acriticalreview.IntJGynecolPathol1993Apr;12(2):186-192.

(59)KyrgiouM,TsoumpouI,VrekoussisT,Martin-HirschP,ArbynM,PrendivilleW,etal.Theup-to-dateevidenceoncolposcopypracticeandtreatmentofcervicalintraepithelialneoplasia:theCochranecolposcopy&cervicalcytopathologycollaborativegroup(C5group)approach.CancerTreatRev2006Nov;32(7):516-523.

(60)WalkerP,DexeusS,DePaloG,BarrassoR,CampionM,GirardiF,etal.Internationalterminologyofcolposcopy:anupdatedreportfromtheInternationalFederationforCervicalPathologyandColposcopy.ObstetGynecol2003Jan;101(1):175-177.

(61)PrendivilleW.ThetreatmentofCIN:whataretherisks?Cytopathology2009Jun;20(3):145-153.

(62)BornsteinJ.PersonalCommunicationRegardingManuscriptSubmittedforPublication.July2011.

(63)StolerMH,SchiffmanM,AtypicalSquamousCellsofUndeterminedSignificance-Low-gradeSquamousIntraepithelialLesionTriageStudy(ALTS)Group.Interobserverreproducibilityofcervicalcytologicandhistologicinterpretations:realisticestimatesfromtheASCUS-LSILTriageStudy.JAMA2001Mar21;285(11):1500-1505.

(64)PetryKU.Managementoptionsforcervicalintraepithelialneoplasia.BestPractResClinObstetGynaecol2011Oct;25(5):641-651.

(65)MoscickiAB,ShiboskiS,HillsNK,PowellKJ,JayN,HansonEN,etal.Regressionoflow-gradesquamousintra-epitheliallesionsinyoungwomen.Lancet2004Nov6-12;364(9446):1678-1683.

(66)TheSocietyforColposcopyandCervicalPathologyofSingapore.Structuredcolposcopytrainingprogrammeandregistrationforms.Availableat:http://www.sccps.org/training.htm.Accessed02/13,2006.

28of34

(67)JonesRW,BestDV,CoxB,FitzgeraldNW,HillM,JenningsP,etal.Guidelinesforthemanagementofwomenwithabnormalcervicalsmears1998.NZMedJ2000May12;113(1109):168-171.

(68)RoyalCollegeofObstetriciansandGynaecologists.Standardsincolposcopy.Availableat:http://www.rcog.org.uk/index.asp?PageID=1170.Accessed02/13,2006.

(69)NationalCervicalScreeningProgram(Australia).ScreeningtoPreventCervicalCancer:GuidelinesfortheManagementofAsymptomaticWomenwithScreenDetectedAbnormalities.2005;Availableat:http://www.health.gov.au/internet/screening/publishing.nsf/Content/guide.Accessed03/16,2011.

(70)McCredieMR,SharplesKJ,PaulC,BaranyaiJ,MedleyG,JonesRW,etal.Naturalhistoryofcervicalneoplasiaandriskofinvasivecancerinwomenwithcervicalintraepithelialneoplasia3:aretrospectivecohortstudy.LancetOncol2008May;9(5):425-434.

(71)Ghaem-MaghamiS,SagiS,MajeedG,SoutterWP.Incompleteexcisionofcervicalintraepithelialneoplasiaandriskoftreatmentfailure:ameta-analysis.LancetOncol2007Nov;8(11):985-993.

(72)Ghaem-MaghamiS,SoutterWP.Re:EffectofmarginstatusoncervicalintraepithelialneoplasiarecurrencefollowingLLETZinwomenover50years.BJOG2009Feb;116(3):465.

(73)ASCUS-LSILTriageStudy(ALTS)Group.Resultsofarandomizedtrialonthemanagementofcytologyinterpretationsofatypicalsquamouscellsofundeterminedsignificance.AmJObstetGynecol2003Jun;188(6):1383-1392.

(74)MooreK,CoferA,ElliotL,LanneauG,WalkerJ,GoldMA.Adolescentcervicaldysplasia:histologicevaluation,treatment,andoutcomes.AmJObstetGynecol2007Aug;197(2):141.e1-141.e6.

(75)HowlettRI,MarrettLD,InnesMK,RosenBP,McLachlinCM.DecreasingincidenceofcervicaladenocarcinomainOntario:isthisrelatedtoimprovedendocervicalPaptestsampling?IntJCancer2007Jan15;120(2):362-367.

(76)EtheringtonIJ,LuesleyDM.Adenocarcinomainsituofthecervix-controversiesindiagnosisandtreatment.JLowGenitTractDis2001Apr;5(2):94-98.

(77)CullimoreJE,LuesleyDM,RollasonTP,ByrneP,BuckleyCH,AndersonM,etal.Aprospectivestudyofconizationofthecervixinthemanagementofcervicalintraepithelialglandularneoplasia(CIGN)--apreliminaryreport.BrJObstetGynaecol1992Apr;99(4):314-318.

29of34

(78)BertrandM,LickrishGM,ColganTJ.Theanatomicdistributionofcervicaladenocarcinomainsitu:implicationsfortreatment.AmJObstetGynecol1987Jul;157(1):21-25.

(79)SalaniR,PuriI,BristowRE.Adenocarcinomainsituoftheuterinecervix:ametaanalysisof1278patientsevaluatingthepredictivevalueofconizationmarginstatus.AmJObstetGynecol2009Feb;200(2):182.e1-182.e5.

(80)BrysonP,StulbergR,ShepherdL,McLellandK,JeffreyJ.IselectrosurgicalloopexcisionwithnegativemarginssufficienttreatmentforcervicalACIS?GynecolOncol2004May;93(2):465-468.

(81)SeratiM,UccellaS,LaterzaRM,SalvatoreS,BerettaP,RivaC,etal.Naturalhistoryofcervicalintraepithelialneoplasiaduringpregnancy.ActaObstetGynecolScand2008;87(12):1296-1300.

(82)FaderAN,AlwardEK,NiederhauserA,ChiricoC,LesnockJL,ZwieslerDJ,etal.Cervicaldysplasiainpregnancy:amulti-institutionalevaluation.AmJObstetGynecol2010Aug;203(2):113.e1-113.e6.

(83)SoutterWP,SasieniP,PanoskaltsisT.Long-termriskofinvasivecervicalcanceraftertreatmentofsquamouscervicalintraepithelialneoplasia.IntJCancer2006Apr15;118(8):2048-2055.

(84)MelnikowJ,McGahanC,SawayaGF,EhlenT,ColdmanA.Cervicalintraepithelialneoplasiaoutcomesaftertreatment:long-termfollow-upfromtheBritishColumbiaCohortStudy.JNatlCancerInst2009May20;101(10):721-728.

(85)SoutterWP,deBarrosLopesA,FletcherA,MonaghanJM,DuncanID,ParaskevaidisE,etal.Invasivecervicalcancerafterconservativetherapyforcervicalintraepithelialneoplasia.Lancet1997Apr5;349(9057):978-980.

(86)MitchellMF,Tortolero-LunaG,CookE,WhittakerL,Rhodes-MorrisH,SilvaE.Arandomizedclinicaltrialofcryotherapy,laservaporization,andloopelectrosurgicalexcisionfortreatmentofsquamousintraepitheliallesionsofthecervix.ObstetGynecol1998Nov;92(5):737-744.

(87)ParaskevaidisE,ArbynM,SotiriadisA,DiakomanolisE,Martin-HirschP,KoliopoulosG,etal.TheroleofHPVDNAtestinginthefollow-upperiodaftertreatmentforCIN:asystematicreviewoftheliterature.CancerTreatRev2004Apr;30(2):205-211.

(88)ArbynM,ParaskevaidisE,Martin-HirschP,PrendivilleW,DillnerJ.ClinicalutilityofHPV-DNAdetection:triageofminorcervicallesions,follow-upofwomentreatedforhigh-gradeCIN:anupdateofpooledevidence.GynecolOncol2005Dec;99(3Suppl1):S7-11.

(89)CuzickJ,ArbynM,SankaranarayananR,TsuV,RoncoG,MayrandMH,etal.Overviewofhumanpapillomavirus-basedandothernoveloptionsforcervical

30of34

cancerscreeningindevelopedanddevelopingcountries.Vaccine2008Aug19;26Suppl10:K29-41.

(90)MeijerCJ,BerkhofJ,CastlePE,HesselinkAT,FrancoEL,RoncoG,etal.GuidelinesforhumanpapillomavirusDNAtestrequirementsforprimarycervicalcancerscreeninginwomen30yearsandolder.IntJCancer2009Feb1;124(3):516-520.

(91)ChanBK,MelnikowJ,SleeCA,ArellanesR,SawayaGF.Posttreatmenthumanpapillomavirustestingforrecurrentcervicalintraepithelialneoplasia:asystematicreview.AmJObstetGynecol2009Apr;200(4):422.e1-422.e9.

(92)KitchenerHC,WalkerPG,NelsonL,HadwinR,PatnickJ,AnthonyGB,etal.HPVtestingasanadjuncttocytologyinthefollowupofwomentreatedforcervicalintraepithelialneoplasia.BJOG2008Jul;115(8):1001-1007.

(93)MayrandMH,AbrahamowiczM,JamesBentleyJ,BessetteP,CoutléeF,EhlenT,ElitL,Fung-Kee-FungM,LauS,PlanteM.Colposcopyvs.HPVtestingtoidentitypersistentpre-cancersposttreatment:theCoHIPPtrial.HPV2010Conference2010June2010.

(94)terHaar-vanEckSA,Rischen-VosJ,Chadha-AjwaniS,HuikeshovenFJ.Theincidenceofcervicalintraepithelialneoplasiaamongwomenwithrenaltransplantinrelationtocyclosporine.BrJObstetGynaecol1995Jan;102(1):58-61.

(95)DavidM,OlbrichC,NeuhausR,LichteneggerW.Occurrenceofsuspiciouschangesincervixcytologyinwomenafterlivertransplantation.GeburtshilfeFrauenheilkd1995Aug;55(8):431-434.

(96)CliffordGM,FranceschiS.CancerriskinHIV-infectedpersons:influenceofCD4(+)count.FutureOncol2009Jun;5(5):669-678.

(97)DennyL,BoaR,WilliamsonAL,AllanB,HardieD,StanR,etal.Humanpapillomavirusinfectionandcervicaldiseaseinhumanimmunodeficiencyvirus-1-infectedwomen.ObstetGynecol2008Jun;111(6):1380-1387.

(98)BoardmanLA,CotterK,RakerC,Cu-UvinS.Cervicalintraepithelialneoplasiagrade2orworseinhumanimmunodeficiencyvirus-infectedwomenwithmildlyabnormalcervicalcytology.ObstetGynecol2008Aug;112(2Pt1):238-243.

(99)KitchenerH,NelsonL,AdamsJ,MesherD,SasieniP,CubieH,etal.ColposcopyisnotnecessarytoassesstherisktothecervixinHIV-positivewomen:aninternationalcohortstudyofcervicalpathologyinHIV-1positivewomen.IntJCancer2007Dec1;121(11):2484-2491.

(100)FoulotH,HeardI,PotardV,CostagliolaD,ChapronC.SurgicalmanagementofcervicalintraepithelialneoplasiainHIV-infectedwomen.EurJObstetGynecolReprodBiol2008Dec;141(2):153-157.

31of34

Table2:The2001BethesdaSystemTerminologyforCytology(permissionrequested)

AdaptedfromSolomonDetal.(15)

SquamousCell

¨ Atypicalsquamouscells

o Ofundeterminedsignificance

o Cannotexcludehigh-gradesquamousintraepitheliallesions

¨ Low-gradesquamousintraepitheliallesions-encompassinghumanpapillomavirus,milddysplasiaandCIN1

¨ High-gradesquamousintraepitheliallesions-encompassingmoderateandseveredysplasia,carcinomainsitu,CIN2andCIN3

¨ Squamouscellcarcinoma

GlandularCell

¨ Atypicalglandularcells(specifyendocervical,endometrial,ornototherwisespecified)

¨ Atypicalglandularcells,favorneoplasia(specifyendocervicalornototherwisespecified)

¨ Adenocarcinoma

32of34

Table3:EvolutionofCervicalCancerPrecursors(58)

CINgrade Regression Persistence ProgressiontoCIN3

Progressiontowardsinvasivecancer

CIN1 57% 32% 11% 1%

CIN2 43% 35% 22% 5%

CIN3 32% <56% - >12%

Table4.CriteriaforAblativeMethodsofCINTreatment

ModifiedfromPrendiville2009(61)(permissionrequested)

Ø Thetransformationzone(TZ)mustbefullyvisible

Ø AcolposcopicallydirecteddiagnosticbiopsymustbetakenfromthemostdysplasticareaintheTZ

Ø Theremustbenosuspicionofinvasivedisease

Ø Theremustbenosuspicionofglandulardisease

Ø Thereshouldnotbecytological/histologicaldisparity

Ø Thepatientshouldnothavehadprevioustreatment

CryotherapyisnotrecommendedfortreatmentofCIN3

33of34

Figure1.TransformationZoneCategories

Type I Type II Type III

completely ectocervical

fully visible

small or large ectocervical component

has an endocervical component

fully visible

may have ectocervical component which may

be small or large

has an endocervical component

is not fully visible

may have ectocervical component which may

be small or large

34of34

Glossary

AC AdenocarcinomaAGC-N Atypicalglandularcells-favorneoplasiaAGC-NOS Atypicalglandularcells-nototherwisespecifiedAGUS AtypicalglandularcellsofundeterminedsignificanceAIS AdenocarcinomainsituASC-H Atypicalsquamouscells-cannotexcludehigh-grade

squamousintraepitheliallesionASCUS AtypicalsquamouscellsofundeterminedsignificanceCIN(1,2,3) Cervicalintraepithelialneoplasia(1,2,3)ECC EndocervicalcurettageHPV HumanpapillomavirusHSIL High-gradesquamousintraepitheliallesionLEEP/LLETZ Loopelectrosurgicalexcisionprocedure/largeloop

excisionofthetransformationzoneLSIL LowgradesquamousintraepitheliallesionSCC Squamouscellcarcinoma

SOGC / SCC Clinical Practice Guideline -...

Documents

Transcript of SOGC / SCC Clinical Practice Guideline -...